Alexander Treiber
Overview
Explore the profile of Alexander Treiber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brotschi C, Bolli M, Gatfield J, Heidmann B, Jenck F, Roch C, et al.
ChemMedChem
. 2020 Jan;
15(5):430-448.
PMID: 31945272
The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we...
12.
Brotschi C, Roch C, Gatfield J, Treiber A, Williams J, Sifferlen T, et al.
ChemMedChem
. 2019 May;
14(13):1257-1270.
PMID: 31066976
The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline...
13.
Ichikawa T, Yamada T, Treiber A, Gnerre C, Segrestaa J, Seeland S, et al.
Xenobiotica
. 2018 Feb;
49(3):284-301.
PMID: 29468921
1. The metabolism of the prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-333679) has been investigated in liver microsomes and hepatocytes of rats, dogs, and monkeys....
14.
Gnerre C, Segrestaa J, Seeland S, Aanismaa P, Pfeifer T, Delahaye S, et al.
Xenobiotica
. 2017 Jul;
48(7):704-719.
PMID: 28737453
1. The metabolism of selexipag has been studied in vivo in man and the main excreted metabolites were identified. Also, metabolites circulating in human plasma have been structurally identified and...
15.
Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, et al.
J Pharmacol Exp Ther
. 2017 Jul;
362(3):489-503.
PMID: 28663311
The identification of new sleep drugs poses particular challenges in drug discovery owing to disease-specific requirements such as rapid onset of action, sleep maintenance throughout major parts of the night,...
16.
Ichikawa T, Yamada T, Treiber A, Gnerre C, Nonaka K
Xenobiotica
. 2017 Mar;
48(2):186-196.
PMID: 28277164
1. This study examined the pharmacokinetics, distribution, metabolism and excretion of the selective prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-33679). The compounds were investigated following...
17.
Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, et al.
ChemMedChem
. 2016 Jul;
11(19):2132-2146.
PMID: 27390287
Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach. Structure-activity relationship optimization allowed us not only...
18.
Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, et al.
J Med Chem
. 2015 Nov;
58(23):9133-53.
PMID: 26550844
Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause...
19.
de Kanter R, Sidharta P, Delahaye S, Gnerre C, Segrestaa J, Buchmann S, et al.
Clin Pharmacokinet
. 2015 Sep;
55(3):369-80.
PMID: 26385839
Introduction: Macitentan is a novel dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). It is metabolized by cytochrome P450 (CYP) enzymes, mainly CYP3A4, to its active...
20.
Treiber A, Miraval T, Bolli M, Funel J, Segrestaa J, Seeland S
Xenobiotica
. 2015 Sep;
46(3):253-67.
PMID: 26337830
1. The metabolism of the endothelin receptor antagonist macitentan has been characterized in bile duct-cannulated rats and dogs. 2. In both species, macitentan was metabolized along five primary pathways, i.e....